ClinicalTrials.gg
RecruitingNCT07870785CIVIUS2026PALUpdated Oct 15, 2026

Volumetric Visual Fields at Different Distances in Presbyopic Patients Using Occupational (PC-133 and PC-200) and General-Purpose Progressive Addition Lenses

An interventional study of OPAL PC 133 assessment and OPAL PC 200 assessment in Presbyopia, sponsored by University of Seville. Recruiting at 1 site in Spain. Open to participants aged 52 Years to 67 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by University of Seville · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2026, registered Oct 2026).
  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 13, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
52 Years to 67 Years
Sex
All
01

Study summary

This single-center, randomized, double-blind, crossover clinical trial aims to compare the volumetric visual fields provided by two occupational progressive addition lenses (OPLs) optimized for intermediate and near vision in presbyopic patients. The study evaluates Vimax PC 1.5 FWD 133 cm and Vimax PC 1.5 FWD 200 cm lenses and Vimax Fit FRM, all of them with plano distance power and a +2.00 D near addition, in order to determine differences in the extent of clear vision at multiple working distances.

Participants will undergo a comprehensive optometric examination including medical and ocular history, visual acuity assessment, accommodative amplitude measurement, autorefraction, interpupillary distance measurement, ocular motility evaluation, confrontation visual fields, Amsler grid testing, and binocular vision assessment. Visual field measurements will then be performed using both study lenses under standardized conditions. Subjects will be instructed to maintain a fixed head position while identifying optotypes located at distances of 4 m, 2 m, 1.33 m, 80 cm, 40 cm, and 25 cm. Both lenses will be tested in random order under masked conditions so that neither participants nor investigators know which lens design is being evaluated during each phase.

At least 23 presbyopic participants are expected to be enrolled. The study procedures are non-invasive and are anticipated to be completed in a single one-hour visit, although additional sessions may be scheduled if necessary. No significant risks are expected beyond possible transient visual fatigue associated with the duration of testing.

The primary objective is to determine which occupational progressive lens design provides a greater spatial volume of clear vision and wider horizontal and vertical visual fields at different intermediate and near distances. The findings may contribute to improving personalized recommendations of occupational lenses according to patients' visual demands and working distances.

02

Conditions studied

  • Presbyopia

Browse trials for

Keywords

  • Occupational progressive lenses
  • Presbyopia
  • Visual field depth
  • Visual field volume
  • Visual acuity
03

In context

Presbyopia

330 studies on the registry are indexed under Presbyopia; 35 are open to participants now.

This study's planned enrollment of 28 is below the median of 60 across 271 interventional studies indexed under Presbyopia.

Browse Presbyopia studies →

Lead sponsor

University of Seville is the lead sponsor of 129 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
52 Years to 67 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Spherical ametropia for distance vision ≤ ±4.00 D and astigmatic ametropia ≤ 1.00 D.

      • Decimal VA ≥ 0.8, either uncorrected (UCVA) or corrected (BCVA) with monofocal contact lenses.
      • Patients with a nasopupillary distance (NPD) of 31 mm, with a tolerance of ±2 mm in each eye

Exclusion criteria

Exclusion Criteria:

  • Astigmatism greater than ±1.00 D.
  • Patients wearing progressive contact lenses.
  • Patients who have undergone cataract surgery or have monofocal or multifocal intraocular lenses.
  • Anisometropia greater than 2.50 D.
  • Decimal distance visual acuity \< 0.8 (UCVA or BCVA) with monofocal contact lenses.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    OPL designed for PC use and 133cm of visual depth field

    Occupational progressive lenses designed to provide clear vision from 133 cm to 40 cm, with a wider visual field optimized for monitor-based environments with a depth of field between 60 and 80 cm. These lenses, designated L1, were custom ordered with neutral distance power and a near addition of +2.00 D, a vertex distance of 13 mm, pantoscopic tilt of 8°, wrap angle of 6°, working distance of 40 cm, inset of 2.5 mm in both eyes, and NPD of 31 mm in each eye

    Device: OPAL PC 133 assessment

  • Experimental
    OPL designed for PC use and 200cm of visual depth field

    Occupational progressive lenses designed to provide clear vision from 200 cm to 40 cm, with a wider visual field optimized for monitor-based environments with a depth of field between 60 and 80 cm. These lenses, designated L1, were custom ordered with neutral distance power and a near addition of +2.00 D, a vertex distance of 13 mm, pantoscopic tilt of 8°, wrap angle of 6°, working distance of 40 cm, inset of 2.5 mm in both eyes, and NPD of 31 mm in each eye

    Device: OPAL PC 200 assessment

  • Experimental
    PAL

    Progressive additional lenses custom ordered with neutral distance power and a near addition of +2.00 D, vertex dis-tance of 13 mm, pantoscopic tilt of 8°, wrap angle of 6°, working distance of 40 cm, inset of 2.5 mm in both eyes, and NPD of 31 mm in both eyes.

    Device: PAL assessment

Interventions

  • DeviceOPAL PC 133 assessment

    Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist. Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order.

  • DeviceOPAL PC 200 assessment

    Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist. Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order

  • DevicePAL assessment

    Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist. Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order

06

What researchers measure

Primary outcomes

  1. Visual field volume

    It will consist of the volume defined by two parallel surfaces bounded by the visual fields perceived with clear horizontal and vertical vision by the patient between the distances of 4 m and 25 cm while wearing each pair of spectacles. The volume will be calculated using the Heronian formula for the volume of a quadrangular pyramidal frustum.

    Time frame: Immediately after the adjustment of the frame where the lenses were placed, an average of 30 minutes per patient.

Secondary outcomes

  1. Visual fields surface

    Calculation of the visual field surface areas defined by the patient with each lens type at distances of 4 m, 2 m, 1.33 m, 80 cm, 40 cm, and 25 cm. For this purpose, the areas corresponding to the visual field regions of the lens located between the fitting cross and the intermediate and near viewing zones were summed in a 1:2 proportion, respectively, for each measured distance.

    Time frame: Immediately after the adjustment of the frame where the lenses were placed, an average of 30 minutes per patient

07

Study locations

1 of 1 sites recruiting
  • Pharmacy School, University of Seville
    Seville, Andalusia 41012, Spain
    Recruiting
08

References and documents

Study documents

  • Study protocol · Apr 8, 2026

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2026 to primary completion in Jun 2026, 0 months.

Of 38 non-industry interventional studies with no phase under Presbyopia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 0 months is below that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 3 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2026
First posted
Oct 13, 2026
StartActual
Jun 8, 2026
Primary completionActual
Jun 26, 2026
CompletionEst.
Jun 30, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 2 updates
  1. Oct 15, 2026
    Minor edits only
    + 1 other change: responsible party
  2. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07870785
Responsible party
José Manuel Serrano Morales (Principal Investigator, University of Seville) — Principal investigator
First posted
Oct 13, 2026
Start date
Jun 8, 2026
Primary completion
Jun 26, 2026
Completion
Jun 30, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

José Manuel Serrano Morales, PhD
Contact
jsmorales@us.es
0034654686850
José Manuel Serrano Morales, PhD
principal investigator · Pharmacy School, University of Seville

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion